https://www.selleckchem.com/ph....armacological_epigen
The results obtained are expected to contribute to a more complete understanding of the hemodynamic changes resulting from pregnancy. Trastuzumab (Herceptin) is the key systemic therapy for HER2-positive breast cancer. However, the initial response rate is limited to approximately 50% in patients. Moreover, most patients, especially at an advanced stage, eventually develop acquired resistance. Understanding the mechanisms of trastuzumab resistance is crucial for achieving better treatment outcome in this group of patients. A
Like
Comment
Share
